Diabetes Mellitus Attenuates Response to Anti-CD20 Therapy in Primary Membranous Nephropathy Despite Equivalent B-Cell Depletion - PubMed
5 hours ago
- #Anti-CD20 Antibody
- #Membranous Nephropathy
- #Diabetes Mellitus
- Diabetes Mellitus (DM) reduces response to anti-CD20 therapy in Primary Membranous Nephropathy (MN) despite similar B-cell depletion.
- Study compared MN patients with and without DM, showing lower remission rates in diabetic patients at 9 and 12 months.
- No significant differences in B-cell depletion and immunological remission rates between the groups.
- Diabetic MN patients had overall remission rates of 77% at 9 months and 86% at 12 months, compared to 94% and 97% in non-diabetic patients.
- Subgroup analyses confirmed consistently poorer responses in diabetic patients across multiple strata.
- Safety profiles were similar between diabetic and non-diabetic MN patients.
- Tight glycemic control, early supplementary anti-CD20 dosing, and combined immunosuppressive regimens may improve outcomes for diabetic MN patients.